BioElectronics Corp. engages in the development of wearable, nueromodulation devices for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications. The company is headquartered in Frederick, Maryland. The company went IPO on 2004-04-12. Its pulsed shortwave therapy technology (PSWT) uses low-power pulsed electromagnetic fields to regulate electrical activity of the nervous system. The Company’s product line includes ActiPatch Musculoskeletal Pain Therapy, and RecoveryRx Post-operative and Chronic Wounds Therapy, which are sold by or on the order of medical professionals. PSWT is a non-invasive electromagnetic therapy designed to reduce pain and enhance life in patients with chronic musculoskeletal conditions. PSWT has no systemic side effects and can be self-administered at home. The ActiPatch product provides advanced long-lasting pain relief using Electromagnetic Pulse Therapy and works great for back pain, knee pain, muscle & joint pain, arthritis, sciatica, fibromyalgia, strains, sprains and more.
BIEL'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
BioElectronics Corp'in en son EPS'si $ olup, $ beklentilerini .
BioElectronics Corp BIEL'ün son çeyrekteki geliri nasıl performans gösterdi?
BioElectronics Corp'in son çeyrek geliri $
BioElectronics Corp'in gelir tahmini nedir?
Wall Street analistine göre, BioElectronics Corp'in gelir tahmini $ ile $ arasında değişmektedir.
BioElectronics Corp'in kazanç kalite puanı nedir?
BioElectronics Corp'in kazanç kalite puanı B+/49.34351'dir. Puan, karlılık, büyüme, nakit üretimi ve sermaye tahsisi ile kaldıraç olmak üzere dört boyuta dayanır.
BioElectronics Corp kazançlarını ne zaman rapor eder?
BioElectronics Corp'in bir sonraki kazanç raporu 2024-09-13'te bekleniyor